ABBISKO-B's FGFR4 Inhibitor Irpagratinib Receives FDA Fast Track Designation for Liver Cancer Treatment

Stock News02-10 08:08

ABBISKO-B (02256) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its self-developed highly selective small-molecule FGFR4 inhibitor Irpagratinib (also known as ABSK-011). The designation applies to the treatment of hepatocellular carcinoma (HCC) patients who have previously received immune checkpoint inhibitors and multi-target kinase inhibitors and exhibit FGF19 overexpression. This FDA designation will help accelerate the global clinical development and regulatory review process for Irpagratinib. ABBISKO-B will continue to advance the international clinical deployment of this project, aiming to provide more precise and effective innovative treatment options for HCC patients worldwide.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment